Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
Ignacio Garrido‐Laguna(Cancer Research Center), Manuel Hidalgo(Spanish National Cancer Research Centre)
Cited by 72
Related Papers
An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
|Clinical Cancer Research|2006|412
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
|British Journal of Cancer|2013|291
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
|Molecular Cancer Therapeutics|2010|246